QURE Research and Charts

QURE - uniQure NV (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-09-15)

Last 14.84	Change ⇓ -1.65 (-10.04%)	Volume 2,992,459
	Open 16.55	High 16.61	Low 14.71

8EMA (Daily) 16.53	40EMA (Daily) 15.77	50EMA (Daily) 15.57	STO (Daily) 52.094	MACD Hist (Daily) -0.412
8EMA (Weekly) 15.686	40EMA (Weekly) 13.67	50EMA (Weekly) 13.15	STO (Weekly) 70.092	MACD Hist (Weekly) 0.009


Company Profile
uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.